AU
CA
NZ
UK
US
IND
Kalkine has a fully transformed New Avatar.
Last update at 2025-06-13T06:10:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla
Wed 28 Jun 23, 10:30 AMDiamond Equity Research Initiates Coverage on Imugene Ltd. (ASX: IMU)
Thu 29 Sep 22, 01:00 PMHere's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation
Sun 07 Aug 22, 10:15 PM| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | -39.17108M | -37.86917M | -18.45536M | -10.50800M | -7.77536M |
| Minority interest | - | - | - | - | - |
| Net income | -39.17108M | -37.97592M | -25.76667M | -14.58706M | -7.77568M |
| Selling general administrative | 17.77M | 12.10M | 9.44M | 4.29M | 3.81M |
| Selling and marketing expenses | 0.51M | 0.33M | 0.15M | 0.28M | 0.43M |
| Gross profit | - | - | - | - | 4.13M |
| Reconciled depreciation | 0.19M | 0.20M | 0.10M | 0.08M | 0.06M |
| Ebit | -51.29082M | -37.65758M | -18.34433M | -10.50297M | -7.76893M |
| Ebitda | -51.10050M | -37.45422M | -18.24013M | -10.42047M | -7.70567M |
| Depreciation and amortization | 0.19M | 0.20M | 0.10M | 0.08M | 0.06M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -51.29082M | -37.65758M | -18.34433M | -10.50297M | -7.76893M |
| Other operating expenses | 51.29M | 50.67M | 25.67M | 14.88M | 12.39M |
| Interest expense | - | 0.11M | 0.11M | 0.00503M | 0.00611M |
| Tax provision | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Interest income | 1.88M | 0.19M | 0.13M | 0.30M | 0.41M |
| Net interest income | 1.85M | 0.07M | 0.01M | 0.30M | 0.41M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -1.84994M | 0.11M | 7.31M | 4.08M | 0.00032M |
| Total revenue | - | 0.00000M | 0.00000M | 4.21M | 4.54M |
| Total operating expenses | 51.29M | 50.67M | 25.67M | 14.88M | 12.39M |
| Cost of revenue | - | - | - | - | - |
| Total other income expense net | 10.27M | -0.21159M | -0.11103M | -0.00503M | -0.00643M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -39.17108M | -37.86917M | -18.45536M | -10.50800M | -7.77536M |
| Net income applicable to common shares | -37.91489M | -37.86917M | -18.45536M | -10.50800M | -7.77536M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Total assets | 151.40M | 195.81M | 147.61M | 71.81M | 65.20M |
| Intangible assets | 34.12M | 30.49M | 32.69M | 34.89M | 30.46M |
| Earning assets | - | - | - | - | - |
| Other current assets | 7.31M | 0.40M | 1.11M | 0.17M | 0.19M |
| Total liab | 33.14M | 7.44M | 8.90M | 6.79M | 5.40M |
| Total stockholder equity | 118.25M | 188.37M | 138.70M | 65.02M | 59.81M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 22.42M | 1.92M | 1.42M | 2.85M | 1.43M |
| Common stock | 370.31M | 314.40M | 230.79M | 113.11M | 92.80M |
| Capital stock | 370.31M | 314.40M | 230.79M | 113.11M | 104.89M |
| Retained earnings | -289.83175M | -142.69219M | -103.52112M | -65.65194M | -47.31026M |
| Other liab | - | 0.99M | 0.99M | 2.17M | 2.49M |
| Good will | - | - | - | - | - |
| Other assets | - | 0.02M | 0.03M | 0.02M | 0.02M |
| Cash | 93.11M | 153.15M | 99.89M | 29.49M | 30.11M |
| Cash and equivalents | - | 49.54M | 29.00M | 21.00M | 25.00M |
| Total current liabilities | 29.30M | 6.08M | 7.42M | 4.46M | 2.90M |
| Current deferred revenue | - | 1.63M | 1.30M | 0.74M | 0.39M |
| Net debt | -91.56061M | -152.59719M | -99.21429M | -29.21600M | -30.03742M |
| Short term debt | 0.91M | 0.19M | 0.18M | 0.11M | 0.06M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 1.55M | 0.55M | 0.67M | 0.27M | 0.07M |
| Other stockholder equity | - | -172.96587M | -127.26763M | -47.45497M | -45.48730M |
| Property plant equipment | - | 0.68M | 0.86M | 0.47M | 0.16M |
| Total current assets | 113.03M | 164.40M | 113.77M | 36.32M | 34.49M |
| Long term investments | 2.41M | 0.22M | 0.25M | 0.12M | 0.08M |
| Net tangible assets | - | 159.14M | 106.02M | 30.12M | 29.35M |
| Short term investments | 1.44M | - | -0.00000M | - | - |
| Net receivables | 12.62M | 10.85M | 12.77M | 6.66M | 4.19M |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts payable | 5.97M | 2.34M | 4.51M | 0.76M | 1.01M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 37.77M | 16.66M | 11.44M | 17.56M | 14.32M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | 104.89M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.13M | 0.02M | 0.03M | 0.02M | 0.02M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 38.36M | 31.41M | 33.84M | 35.49M | 30.71M |
| Capital lease obligations | - | 0.55M | 0.67M | 0.27M | 0.07M |
| Long term debt total | - | 0.36M | 0.49M | 0.17M | 0.00840M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | 1.89M | -0.13717M | -0.03456M | -0.03064M | -0.02969M |
| Change to liabilities | -1.38542M | 2.85M | 0.03M | -0.99994M | 1.89M |
| Total cashflows from investing activities | 1.89M | -0.22099M | -5.32640M | -1.20665M | 0.25M |
| Net borrowings | -0.14741M | -0.01081M | 0.07M | -0.05356M | -0.04114M |
| Total cash from financing activities | 82.98M | 101.34M | 17.99M | 22.71M | 18.77M |
| Change to operating activities | 0.71M | -0.94002M | 0.02M | 0.01M | -0.06428M |
| Net income | -37.91489M | -37.86917M | -18.45536M | -10.50800M | -7.77568M |
| Change in cash | 53.26M | 70.40M | -0.61973M | 11.06M | 11.23M |
| Begin period cash flow | 99.89M | 29.49M | 30.11M | 19.05M | 7.82M |
| End period cash flow | 153.15M | 99.89M | 29.49M | 30.11M | 19.05M |
| Total cash from operating activities | -31.47096M | -30.84814M | -13.28001M | -10.43777M | -7.90949M |
| Issuance of capital stock | 88.17M | 108.88M | 18.05M | 24.57M | 20.26M |
| Depreciation | 2.39M | 2.41M | 1.96M | 0.08M | 0.06M |
| Other cashflows from investing activities | 1.89M | 0.17M | 0.16M | 0.31M | 0.41M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | 1.09M | -6.10750M | -2.45527M | -0.03357M | -2.30664M |
| Sale purchase of stock | -5.04192M | -6.15137M | -0.12557M | -1.80108M | -1.44396M |
| Other cashflows from financing activities | -0.14741M | -1.38504M | 0.06M | -0.05859M | -0.04725M |
| Change to netincome | 3.64M | 8.81M | 5.62M | 1.01M | 0.28M |
| Capital expenditures | 0.00000M | 0.28M | 5.45M | 1.49M | 0.14M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 1.09M | -6.10750M | -2.45527M | -0.03357M | 1.87M |
| Stock based compensation | 5.64M | 4.10M | 5.56M | 1.27M | - |
| Other non cash items | 4.05M | 4.61M | 3.21M | -0.01226M | 7.71M |
| Free cash flow | -31.47096M | -31.12513M | -18.72776M | -11.92446M | -8.05347M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (AUD) | Price (AUD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to EBITDA (x) | |
|---|---|---|---|---|---|---|---|---|
| IMU Imugene Ltd |
- -% | 0.01 | - | - | 56.40 | 1.94 | -15.5112 | |
| CSL CSL Ltd |
-2.19 0.91% | 238.86 | 28.85 | 33.67 | 7.67 | 4.14 | 5.94 | 18.44 |
| TLX Telix Pharmaceuticals Ltd |
-0.87 3.39% | 24.78 | 183.21 | 21.01 | 10.96 | 15.11 | 10.80 | 91.38 |
| MSB Mesoblast Ltd |
-0.055 2.97% | 1.79 | - | 454.55 | 414.37 | 3.34 | 67.90 | -9.8623 |
| NEU Neuren Pharmaceuticals Ltd |
-0.8 5.76% | 13.10 | 13.00 | 81.97 | 8.10 | 4.86 | 7.25 | 8.80 |
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy CHECKvacc in phase 1 clinical trial for triple negative breast cancer; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic and advanced gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. The company has a research collaboration with NeoImmuneTech to enhance cancer treatments. Imugene Limited is based in Sydney, Australia.
4-6 Bligh Street, Sydney, NSW, Australia, 2000
| Name | Title | Year Born |
|---|---|---|
| Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD | Exec. Chairman | 1956 |
| Ms. Leslie Chong | CEO, MD & Exec. Director | NA |
| Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D. | Chief Technology Officer | NA |
| Dr. Monil Shah M.B.A., Pharm.D. | Chief Bus. Officer | NA |
| Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD | Chief Financial Officer | 1966 |
| Ms. Ursula McCurry | Sr. VP of Clinical Operations | NA |
| Dr. Giovanni Selvaggi | Chief Medical Officer | NA |
| Mr. Nathan Jong C.A. | Joint Company Sec. | NA |
| Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD | Executive Chairman | 1956 |
| Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD | Executive Chairman | 1956 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...